{
    "ticker": "ZNTL",
    "name": "Zynerba Pharmaceuticals, Inc.",
    "description": "Zynerba Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing innovative treatments for neuropsychiatric disorders and pain conditions through its proprietary transdermal cannabinoid formulations. Founded in 2007 and headquartered in Devon, Pennsylvania, Zynerba focuses on leveraging the therapeutic potential of cannabinoids, specifically through its lead product candidate, Zygel, a cannabidiol (CBD) gel designed for the treatment of conditions such as Fragile X syndrome and osteoarthritis. The company's innovative approach targets the endocannabinoid system by delivering cannabinoids directly through the skin, offering a non-invasive and potentially safer alternative to traditional methods of administration. Zynerba is committed to advancing the science of cannabinoid therapy and is actively involved in clinical trials to evaluate the efficacy and safety of its products. By prioritizing patient-centric research, Zynerba aims to unlock new possibilities for those suffering from debilitating conditions, enhancing their quality of life. The company's mission is to provide accessible, effective therapies that can improve the lives of patients and their families, while also contributing to the broader understanding of cannabinoid-based treatments in the medical community.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Devon, Pennsylvania, USA",
    "founded": "2007",
    "website": "https://zynerba.com",
    "ceo": "Armando Anido",
    "social_media": {
        "twitter": "https://twitter.com/Zynerba",
        "linkedin": "https://www.linkedin.com/company/zynerba-pharmaceuticals"
    },
    "investor_relations": "https://investors.zynerba.com",
    "key_executives": [
        {
            "name": "Armando Anido",
            "position": "Chairman and CEO"
        },
        {
            "name": "Gina W. R. C. Junghans",
            "position": "Chief Financial Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Cannabinoid Therapeutics",
            "products": [
                "Zygel"
            ]
        }
    ],
    "seo": {
        "meta_title": "Zynerba Pharmaceuticals, Inc. | Innovative Cannabinoid Therapies",
        "meta_description": "Explore Zynerba Pharmaceuticals, Inc., a leader in cannabinoid therapy development for neuropsychiatric disorders. Discover our innovative products and commitment to patient care.",
        "keywords": [
            "Zynerba",
            "Cannabinoid Therapy",
            "Neuropsychiatric Disorders",
            "Zygel",
            "Pharmaceuticals",
            "Osteoarthritis",
            "Fragile X Syndrome"
        ]
    },
    "faq": [
        {
            "question": "What is Zynerba Pharmaceuticals known for?",
            "answer": "Zynerba Pharmaceuticals is known for developing cannabinoid-based therapies for neuropsychiatric disorders and pain conditions."
        },
        {
            "question": "Who is the CEO of Zynerba Pharmaceuticals?",
            "answer": "Armando Anido is the Chairman and CEO of Zynerba Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Zynerba Pharmaceuticals headquartered?",
            "answer": "Zynerba Pharmaceuticals is headquartered in Devon, Pennsylvania, USA."
        },
        {
            "question": "What is Zynerba's main product?",
            "answer": "Zynerba's main product is Zygel, a transdermal cannabidiol gel."
        },
        {
            "question": "When was Zynerba Pharmaceuticals founded?",
            "answer": "Zynerba Pharmaceuticals was founded in 2007."
        }
    ],
    "competitors": [
        "GWPH",
        "CRON",
        "NBEV"
    ],
    "related_stocks": [
        "AMGN",
        "PFE",
        "BMY",
        "JNJ"
    ]
}